The implementation of these innovative strategies is expected to facilitate the translation of SGK1-targeted therapies from the laboratory to the clinic, and provide new solutions for the treatment of metabolic bone diseases, diabetes, hypertension, and tumors. The gene discussed is SGK1; the disease is Hypertension.